ARS Pharmaceuticals, Inc. — Director's Dealing 2024

Oct 17, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ARS Pharmaceuticals, Inc. (SPRY)
CIK: 0001671858
Period of Report: 2024-10-16

Reporting Person: Scott Kathleen D. (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2024-10-16	Common Stock	M	12500	$1.50	Acquired	17449	Direct
2024-10-16	Common Stock	S	12500	$16	Disposed	4949	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2024-10-16	Stock Option (Right to Buy)	$1.50	M	12500	Disposed	2032-02-29	Common Stock (12500)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	8250	Indirect

Footnotes

F1: The Reporting Person inadvertently added the holdings of Scott 2008 Trust Dated 3/28/08 (the "Trust") as directly held on her Form 4 filed on August 20, 2024. As of the date of that Form 4, the Reporting Person owned 8,250 shares indirectly through the Trust.

F2: The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 27, 2024.

F3: By the Trust.

F4: Immediately exercisable.